Infantile hemangiomas are composed of endothelial cells (ECs) 
Introduction
Infantile hemangioma, the most common tumor of infancy, is characterized by rapid proliferation of the endothelial cells followed by slow spontaneous involution. 1 This transition from the proliferating phase to the involuting phase represents a gradient of cellular activity from unregulated proliferation to apoptosis. The molecular events that control the evolution of hemangioma remain obscure. Both intrinsic and extrinsic anomalies have been suggested to underlie the primary defect. [2] [3] [4] [5] [6] Recent studies showing that hemangioma-derived endothelial cells (HemECs) are clonal provide support for an intrinsic defect. 4, 6 We and others have identified endothelial progenitor cells (EPCs) in hemangioma tissue and circulating blood of patients with hemangiomas, respectively. 7, 8 These findings suggest that a hemangioma may arise from the clonal expansion of an EPC.
An angioblastic origin for hemangiomas has been envisioned for over a century. In 1863, Virchow questioned whether hemangiomas represented sequestered embryonic mesoderm. 9 Pack and Miller suggested that hemangiomas arise from the localized growth of angioblastic cells. 10 Similarly,
Malan imagined hemangiomas as an activation of dormant angioblasts. 11 Histologic examination of hemangioma ECs reveals an immature phenotype with large nuclei and scant cytoplasm. 12 During the rapid growth phase of hemangiomas, synctial EC hyperplasia, with and without lumens, is seen. In the involuting phase, hyperplasia diminishes and mature vascular channels with
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From defined lumens become prominent. 1 Cultured cells from proliferating phase hemangiomas resemble fetal ECs more than neonatal ECs. 13 The diffuse cytoplasmic localization of CD31 also suggests an immature/precursor state of the ECs isolated from hemangiomas. 13 Our working hypothesis is that hemangiomas are composed of proliferating angioblasts that arise from a single progenitor and the involuting phase represents a delayed and possibly defective differentiation path to mature endothelium. If so, EPCs isolated from the hemangioma tissues (HemEPCs)
should exhibit similar aberrant properties in vitro when compared to HemECs.
We demonstrated previously that HemECs display increased vascular endothelial growth factor (VEGF)-induced migration in response to the angiogenesis inhibitor endostatin (ES); this is in direct contrast to the inhibitory response of human dermal microvascular endothelial cells (HDMECs) from newborn foreskin. 4 In this study, we investigated whether EPCs derived from hemangioma exhibit the same altered cellular behavior in response to ES.
Materials and Methods

Isolation and culture of EPCs and ECs
Hemangioma specimens were obtained with approval of the Committee on 
Endothelial characterization
Flow Cytometry
EPCs and ECs were labeled with fluorescein isothiocynate (FITC)-conjugated 
Indirect Immunofluorescence
Immunofluorescent analysis of cells was carried out with goat anti-human CD31 (Santa Cruz Biotechnology, Santa Cruz, CA), mouse anti-human VECadherin (Immunotech, Westbrook, ME), and rabbit anti-human vWF 
Endostatin experiments -Endostatin experiments were conducted on cells that
were growth factor and serum-starved for 6 hours prior to the assays.
Adhesion Assay
Adhesion of cells was analyzed on 48-well culture plates coated with 0.5% BSA 
Migration Assay
Cellular migration was assayed as described. 4 One hundred μg/mL rat tail collagen type I (0.02N acetic acid) was used to coat 6.5mm Transwells ® with 8.0 µm pore polycarbonate membrane inserts (Corning Life Sciences, Acton, MA) for 24 hours at 37°C, followed by one wash with PBS. Cells were trypsinized and counted. ES pre-treatment of cells (10 ng/mL) was performed in suspension for 30 minutes. 4 For dose-response experiments, ES pre-treatment was performed with 1 ng/mL, 10 ng/mL, 100 ng/mL, 1 μg/mL, and 10 μg/mL ES. Cells were seeded in the upper chamber of the transwell plate at a density of 10,000/well (100 μL volume). Six hundred μL of control media (EBM-2/serum-and growth factor-free) or media with VEGF (5 ng/mL) was added to the lower chamber.
Cells were then allowed to migrate for 4 hours at 37°C. The cells in the upper chamber were gently scraped using a cotton swab. Chilled methanol was added to the lower chamber and the cells on the under side of the insert were fixed.
Cells were visualized by DAPI fluorescence (Vector Laboratories) and counted.
Migration assays was performed on cells cultured for 6, 12, 18, and 24 passages to determine how the VEGF-induced migratory activity was affected by long-term culture.
Proliferation Assay
To determine the effect of ES on cellular proliferation, ECs were seeded on 1 
E-Selectin Expression
Endothelial cells were treated with TNF-α (10 ng/mL) or ES (10 ng/mL) for 5 hours, removed from the culture plates with trypsin, incubated with anti-human Eselectin mAb (Clone 5G11) 17 , and analyzed by flow cytometry as described above.
Oligo microarrays
cDNA from endothelial cells, prepared as described above, was used for For
Statistical Analysis
The data were expressed as means ± SEM and analyzed by ANOVA followed by Student's t-test. Differences were considered significant at values of p < 0.05.
Results
Isolation and characterization of EPCs and ECs
Flow cytometric analysis of isolated cells showed remarkably uniform expression of EC markers, CD31, CD146, CD34, and VEGF-R2 ( Figure 1A ). In addition, the cells were negative for hematopoietic markers, CD45 and CD14. 
ES induces increased adhesion, migration, and proliferation in HemEPCs,
HemECs and cbEPCs
For personal use only. on August 31, 2017. by guest www.bloodjournal.
org From
We previously reported the altered response of HemECs to ES when tested in a VEGF-mediated migration assay. 4 We used this altered response as a "marker"
for the hemangioma phenotype to test whether HemEPCs exhibit the same phenotype as HemECs in this assay. We examined adhesion, migration, and proliferation of normal and hemangioma-derived EPCs and ECs in the presence and absence of ES and VEGF. We found that 10 ng/mL ES increased the adhesion of HemEPCs and HemECs to FN-coated culture plates (Figure 2A) .
Treatment of the HemEPCs and HemECs with VEGF (5 ng/mL) also increased adhesion to FN, but pre-treatment with ES had no additional effect on the VEGFinduced adhesion (Figure 2A ). HDMECs showed no significant changes in adhesion when treated with ES or VEGF (Figure 2A ). We also demonstrated increased adhesion of normal cbEPCs to FN when treated with ES or VEGF.
These findings indicate ES may differentially regulate adhesion of EPCs compared to mature ECs from infantile foreskin.
Next, we examined how ES regulates the migration of the ECs to VEGF. First, the cell counts (seen in Fig 2B) Previous studies have shown a concentration-dependent response of ECs to ES. [18] [19] [20] In order to determine whether the altered behavior of HemEPCs, HemECs, and cbEPCs is concentration-dependent, we carried out the migration assay with varying ES concentrations. This dose-response analysis showed no significant changes in the migration rate of the cells upon treatment with 1 ng/mL to 10 µg/mL ES (data not shown). A similar pattern was observed using cbEPCs.
We employed a third angiogenic assay to evaluate cellular proliferation in response to ES and VEGF. We assayed ES response, either directly after seeding the cells or after allowing cell attachment in the presence of 2% serum for 30 minutes to minimize potential differences in adhesion between the cell types. In both assays, the numbers of HemEPCs, HemECs, and cbEPCs in EStreated group were significantly higher than the control group ( Figure 2C ); whereas ES had no effect on HDMECs. For all ECs, VEGF-induced an approximately 2-fold increase in cell number. Basal proliferation was 2-3-fold higher in HemEPCs, HemECs, and cbEPCs, as compared to HDMECs (data not shown). Consistent with previous studies, ES inhibited VEGF-induced proliferation of HDMECs at 24 hours.
ES-induced migration in EPCs is independent of isolation procedures
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From HemEPCs were isolated by CD133/Ulex selection whereas cbEPCs were isolated by CD34/CD133 selection. Therefore, we tested whether or not EPCs isolated by a different method would also respond to ES. We subjected cbEPCs, purified by Ulex-selection or by CD31-selection, to the ES-mediated migration assay. This showed that cord blood EPCs purified by either method show increased migration in response to ES (data not shown). Thus, human EPCs, isolated from hemangioma or from cord blood, are stimulated rather than inhibited by ES in these assays of in vitro angiogenesis.
HemEPCs retain the angiogenic response to ES in long-term culture whereas normal EPCs shift towards a mature EC response.
We hypothesized that HemEPCs in the proliferating hemangioma differentiate into the apparently mature ECs that line the prominent vascular channels seen in the involuting phase. To test whether such maturation might take place in vitro, we assayed the response to ES in the cells at various time points, corresponding to 2 months of in vitro culture. We defined EC maturation as acquisition of the normal inhibitory response to ES, as seen in HDMECs. Cells were grown in culture, passaged every 4-6 days under identical conditions, and cryopreserved at passage 6, 12, 18 and 24. Cells were then thawed and assayed simultaneously for migration in response to ES, VEGF, and ES + VEGF ( Figure   3A ). The angiogenic response to ES was consistently seen in HemEPCs at Hence, cord blood-derived EPCs and HemECs appear to undergo a shift in ES response towards a mature EC phenotype in culture. In contrast, HemEPCs, which were selected based on the expression of the stem cell marker CD133, retained the angiogenic response to ES under these conditions, perhaps reflecting a defect or delay in endothelial maturation. Basal and VEGF-induced migration were remarkably constant in all EC types from passage 6-24. As seen previously, basal and VEGF-induced migration of HDMECs was lower than HemECs and VEGF-induced migration was inhibited by ES. 4, 18, 19 To determine if relative levels of well-known endothelial markers increased or decreased with growth in culture, RT-PCR (30 cycles) was performed on cells at passage 9 and passage 25: levels of CD31, CD34, VEGF-R2, vWF and VEcadherin did not change in either HemEPCs or cbEPCs ( Figure 3B ). PCR primers used for this analysis are shown in Table 1 . 19 have been shown to interact with ES on the cell surface directly or indirectly and to be involved in the inhibitory effects of ES. To determine if Eselectin might be functioning in the ES stimulatory response, we measured basal, TNF-α-induced, and ES-induced E-selectin levels in HemEPCs and cbEPCs at low and high passage. HDMECs were also analyzed as a positive control. TNF-α induced E-selectin above basal levels in all endothelial populations tested, whereas ES did not ( Figure 4 ). This result indicates that, 1) the EPCs express cytokine-inducible E-selectin as expected for human ECs, and 2) ES does not induce E-selectin expression. These results suggest that E-selectin is not involved in the stimulatory response of the EPCs to ES because basal levels of expression were not appreciably above background.
Analysis of potential ES binding partners
To assess possible functions of integrins, the tyrosine and serine phosphorylation status of three α integrin subunits and two β integrin subunits in control and ES-treated HemEPCs versus HDMECs was measured. In Table 2 , the results are summarized and expressed as the ratio of HemEPC/HDMEC.
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Discussion
We showed that HemEPCs and normal healthy cord blood-derived EPCs share the stimulatory response to endostatin (ES), which was first described for HemECs. 4 ES increased adhesion, migration, and proliferation in HemEPCs, HemECs, and cbEPCs, but inhibited these cellular properties in the mature 
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